[go: up one dir, main page]

WO2012027473A3 - Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus - Google Patents

Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus Download PDF

Info

Publication number
WO2012027473A3
WO2012027473A3 PCT/US2011/048971 US2011048971W WO2012027473A3 WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3 US 2011048971 W US2011048971 W US 2011048971W WO 2012027473 A3 WO2012027473 A3 WO 2012027473A3
Authority
WO
WIPO (PCT)
Prior art keywords
dengue virus
alphavirus
vectored
immunogenic compositions
protein antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/048971
Other languages
English (en)
Other versions
WO2012027473A2 (fr
Inventor
Laura J. White
Robert Edward Johnston
Wahala M.P.B. Wahala
Aravinda De Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of WO2012027473A2 publication Critical patent/WO2012027473A2/fr
Publication of WO2012027473A3 publication Critical patent/WO2012027473A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un vecteur d'alphavirus comprenant un antigène de la protéine E du virus de la dengue. Cette invention concerne également des acides nucléiques codant ou comprenant ce vecteur. L'invention concerne également des compositions multivalentes et des préparations pharmaceutiques comprenant au moins deux vecteurs d'alphavirus ou acides nucléiques selon l'invention. L'invention concerne par ailleurs des méthodes d'administration de ces vecteurs d'alphavirus, de ces acides nucléiques, de ces compositions et/ou de ces préparations pharmaceutiques chez un sujet, notamment pour induire une réponse immunitaire dirigée contre le virus de la dengue, pour traiter l'infection par le virus de la dengue, pour prévenir l'infection par le virus de la dengue et/ou pour protéger un sujet des effets d'une infection par le virus de la dengue.
PCT/US2011/048971 2010-08-24 2011-08-24 Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus Ceased WO2012027473A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37663010P 2010-08-24 2010-08-24
US61/376,630 2010-08-24

Publications (2)

Publication Number Publication Date
WO2012027473A2 WO2012027473A2 (fr) 2012-03-01
WO2012027473A3 true WO2012027473A3 (fr) 2012-08-16

Family

ID=45724045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048971 Ceased WO2012027473A2 (fr) 2010-08-24 2011-08-24 Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus

Country Status (1)

Country Link
WO (1) WO2012027473A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246491B (zh) * 2013-03-15 2019-04-19 宾夕法尼亚大学理事会 针对多种登革病毒亚型的新颖疫苗
KR20160027019A (ko) * 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20090155301A1 (en) * 2006-02-27 2009-06-18 Mason Peter W Pseudoinfectious flavivirus and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165477A (en) * 1995-05-24 2000-12-26 Hawaii Biotechnology Group, Inc. Subunit immonogenic composition against dengue infection
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US20040009469A1 (en) * 2002-02-26 2004-01-15 Maxygen, Inc. Patent Department Novel flavivirus antigens
US20090155301A1 (en) * 2006-02-27 2009-06-18 Mason Peter W Pseudoinfectious flavivirus and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURA J. WHITE ET AL.: "An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice.", JOURNAL OF VIROLOGY., vol. 81, no. 19, 2007, pages 10329 - 10339 *

Also Published As

Publication number Publication date
WO2012027473A2 (fr) 2012-03-01

Similar Documents

Publication Publication Date Title
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
WO2010037027A3 (fr) Immunisation d'oiseaux par administration mucosale de vaccins portés sur vecteur et incapables de se répliquer
WO2007095318A3 (fr) antigenes de la grippe, compositions de vaccins et procedes associes
EP4104854A3 (fr) Vaccins multivalents pour le virus de la rage et les coronavirus
WO2012106377A3 (fr) Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
WO2015044292A8 (fr) Compositions de thérapie génique destinées à être utilisées dans la prévention et/ou le traitement d'une stéatose hépatique non-alcoolique
WO2007022151A3 (fr) Immunisation d'oiseaux par administration de vaccins a vecteurs non repliquants
WO2009026397A3 (fr) Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
WO2013106834A3 (fr) Peptides wt-1 immunogènes et leurs procédés d'utilisation
WO2014018858A3 (fr) Vaccin à protéine de fusion multimérique et produit immunothérapeutique
WO2010019262A3 (fr) Vaccin polyvalent
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
WO2012021730A3 (fr) Vaccin contre le virus syncytial respiratoire (vsr)
WO2012047679A3 (fr) Produits de synthèse d'antigène consensus et vaccins fabriqués à partir de ceux-ci, et procédés d'utilisation de ceux-ci pour traiter le paludisme
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
WO2017142843A8 (fr) Nouvel antigène destiné à être utilisé dans un vaccin antipaludique
WO2017214596A8 (fr) Compositions et procédés pour prévenir et traiter l'infection par le virus zika
WO2011159814A3 (fr) Nouveaux vaccins de rappel recombinants vivants
WO2008054535A3 (fr) Nouveaux vaccins contre l'influenza m2
WO2009080715A3 (fr) Vaccins anti-malaria
MX363149B (es) Vacunas de nucleoproteina de la influenza.
DK3016673T3 (da) Pattedyrsmælkeosteopontin til forbedring af immunreaktion
WO2012174455A3 (fr) Vaccin multivalent contre un streptocoque du groupe a

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820596

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820596

Country of ref document: EP

Kind code of ref document: A2